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Abstract
Brain-derived neurotrophic factor (BDNF) gene regulation has been linked to the pathophysiology of major depressive
disorder (MDD). MDD patients show cognitive deficits, and altered BDNF regulation has a relevant role in
neurocognitive functions. Our goal was to explore the association between BDNF genetic and epigenetic variations
with neurocognitive performance in a group of MDD patients and healthy controls considering possible modulating
factors. The sample included 134 subjects, 64 MDD patients, and 70 healthy controls. Clinical data, childhood
maltreatment, and neurocognitive performance were assessed in all participants. Eleven single nucleotide
polymorphisms (SNPs) and two promoter regions in the BDNF gene were selected for genotype and methylation
analysis. The role of interactions between BDNF genetic and epigenetic variations with MDD diagnosis, sex, and
Childhood Trauma Questionnaire (CTQ) scores was also explored. We observed significant associations between
neurocognitive performance and two BDNF SNPs (rs908867 and rs925946), an effect that was significantly mediated by
methylation values at specific promoter I sites. We identified significant associations between neurocognitive results
and methylation status as well as its interactions with MDD diagnosis, sex, and CTQ scores. Our results support the
hypothesis that BDNF gene SNPs and methylation status, as well as their interactions with modulating factors, can
influence cognition. Further studies are required to confirm the effect of BDNF variations and cognitive function in
larger samples.
Introduction
Major depressive disorder (MDD) is a complex and
highly prevalent psychiatric disorder with a high impact
on quality of life and negative effects on mood, behavior,
and cognition1. Cognitive dysfunction in MDD patients is
a source of disability involving deficits in visual, verbal and
working memory, attention, executive function, and pro-
cessing speed1.
Several neurobiological mechanisms have been involved
in the pathogenesis of MDD and related cognitive
phenotypes, such as the neurotrophic signaling pathway.
The brain-derived neurotrophic factor (BDNF) gene
codes for a neurotrophin that is highly expressed in the
central nervous system (CNS), mediates a variety of
neuroplasticity processes, and has relevant influences on
cognition and behavior2. BDNF is produced in the CNS
and released to the extracellular matrix where it can
interact with its receptors, tropomyosin-related kinase
receptor B (TrkB) and p75 neurotrophin receptor
(p75NTR), which mediate its effects3. Blood BDNF con-
centrations, that have been observed to correlate with
BDNF expression levels in the brain4, are lower in MDD
patients than in healthy controls5.
Research on the role of BDNF single-nucleotide poly-
morphisms (SNPs) in risk for MDD has been centered on
rs62652. This SNP, located in exon IX, results in a valine-
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methionine change in the pro-region of the pro-BDNF
protein, which affects BDNF regulation. Overall, incon-
clusive results have been found, with positive data
showing an association between the minor allele “A” and
MDD6,7 and a lack of robust association in a recent meta-
analysis8. The inconsistency of these results might be
explained by methodological differences, heterogeneity of
MDD clinical subtypes, the influence of modulating
environmental factors and/or by epigenetic mechanisms.
For instance, previous studies suggest that the Met allele
of rs6265 moderates the relationship between stressful life
events in childhood and depression9,10. In addition,
rs6265 has been also associated with brain volumes11,
presence of psychosis and suicidal behavior12, tendency to
chronicity13 and treatment response in melancholic
depression14.
Since BDNF is involved in processes such as neuronal
survival, neurogenesis and long-term potentiation15, ani-
mal studies have reported a relevant role for rs6265 in
motor learning and long-term memory16, which could be
related to changes in hippocampal synaptic plasticity via
downregulation of 5-HT3a receptors in rs6265Met car-
riers17. Human clinical studies have also reported sig-
nificant associations between the BDNF genotype and
cognitive performance18,19, although the results are often
inconsistent and meta-analyses have been negative20.
Genome-wide association studies are beginning to
identify associations of BDNF with several behavioral and
cognitive traits21, such as smoking initiation22, educa-
tional attainment23, highest math class taken23, and the
“worry” genetic-defined subcluster of neuroticism24.
DNA methylation is an epigenetic mechanism asso-
ciated with gene silencing, although some evidence sug-
gests that it may also be associated with active gene
transcription25. Research on methylation patterns in
BDNF of MDD patients has focused on promoter regions
I and IV. Although most research has found that MDD
patients show higher methylation levels at promoter I,
some studies have reported an inverse association in
severely depressed patients26. Research on methylation of
promoter IV has also shown increased methylation levels
in patients with depression when compared to those in
healthy controls27,28. Interestingly, a higher BDNF pro-
moter methylation status has been associated with suici-
dal ideation and suicidal attempt history in depressive
patients29.
Regarding the influence of external factors on gene
regulation through DNA methylation, there is evidence
that DNA methylation of the BDNF gene is modified by
early life negative stressors30,31. Moreover, differences are
observed in specific brain areas and in a sex-specific
manner32. Other factors that have been observed to
influence BDNF methylation are tobacco consumption33,
age34, and pharmacological treatment, with higher
methylation levels of BDNF promoter I in patients under
treatment with antidepressants35.
To our knowledge, there are no previous studies
addressing the involvement of BDNF regulation on cog-
nitive performance in MDD. We hypothesize that specific
methylation of promoter regions of the BDNF will be
associated to poorer performance in neurocognitive tasks.
Our goal was to study the association between BDNF
genetic and epigenetic variation with neurocognitive
performance and to explore the influence of each specific
CpG site within the BDNF gene promoters on cognition,




The sample consisted of 64 MDD patients (72% females,
mean age 57.1 ± 1.3 years) diagnosed according to DSM-
IV-TR criteria (American Psychiatric Association, 2000)
and 71 healthy controls (HCs) (63% females, mean age
54.2 ± 1.3 years. MDD patients were recruited from the
Psychiatry Department at Bellvitge University Hospital
(Hospitalet de Llobregat, Barcelona) while HCs were
recruited from the same geographic region through
advertisements. All participants were unrelated Cauca-
sians of Iberian Peninsula ancestry.
The exclusion criteria were as follows: age less than
18 years, non-Caucasian ethnicity, a diagnosis of other
psychiatric disorders including substance abuse or
dependence (except nicotine), neurological disorders
including dementia, mental retardation, severe medical
conditions, electroconvulsive therapy in the previous year,
pregnancy or puerperium, and corticosteroid treatment in
the previous 3 months.
The sample partially overlaps that used in previous
studies36,37, which explored different hypotheses. The
current participants agreed to provide blood samples for
DNA extraction, genotyping, and methylation studies.
The Clinical Research Ethics Committee (CEIC) of the
Bellvitge University Hospital approved the research pro-
tocol, all participants provided written informed consent
after having received a full explanation of the study.
Clinical assessment
All patients met DSM-IV-TR criteria for MDD and
were interviewed by experienced psychiatrists using the
Mini-International Neuropsychiatric Interview (MINI)38.
HCs were required to have no history of present or past
psychiatric disorders and to show a score lower than 7 in
the 28-item Spanish adaptation of the Goldberg General
Health Questionnaire (GHQ-28). A semistructured
interview was administered to all participants to asses
sociodemographic and clinical variables, substance use
and treatments. Antidepressant treatment was recorded
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using the World Health Organization Anatomical Ther-
apeutic Chemical Classification System39, which measures
treatment as the defined daily dose (DDD), that is, the
assumed average maintenance dose per day for a drug
used for its main indication in adults.
The 17-item Hamilton Depression Rating Scale (HDRS)
was used to assess depression severity40. Treatment
resistance in the MDD group was assessed using the
staging model as proposed by Thase and Rush41, which
defines 5 levels of resistance according to the number and
classes of antidepressants that have failed to produce a
response. The state-trait anxiety inventory (STAI) was
used to evaluate anxiety both in patients and HCs42. The
Childhood Trauma Questionnaire (CTQ), which exam-
ines the exposure to five types of trauma in childhood and
has been previously validated in healthy and clinical
populations, was administered to all participants43. Three
types of childhood maltreatment are focused on abuse
(sexual, physical, and emotional) while two types of mal-
treatment are centered on neglect (physical and emo-
tional). Each type of maltreatment is measured using five
items and each item is rated on a five-point scale.
Neuropsychological assessment
The Spanish version of the Mini-mental State Exam-
ination (MMSE) was used as a screening for dementia.
The following neuropsychological tests were administered
to all participants to assess different cognitive domains:
(1) verbal learning and memory: Hopkins Verbal Learning
Test RevisedTM (HVLT-R); (2) visual learning and mem-
ory: Brief Visuospatial Memory Test RevisedTM (BVMT-
R) and the Rey Complex Figure Test (RCFT), which
includes copy, immediate recall, and delayed recall sub-
scores; (3) working memory: Corsi Block-Tapping Test
(CBTT) and Letter-Number Span (LNS); (4) processing
speed: Trail Making Test Part A (TMT-A), Brief Assess-
ment of Cognition in Schizophrenia – Symbol Coding
(BACS-SC), and category fluency (animal naming); (5)
attention/vigilance: Continuous Performance Test –
Identical Pairs (CPT-IP);(6) selective attention/inter-
ference: Stroop test (direct subscores for words, W; colors,
C; words-colors, WC; interference); (7) reasoning and
problem solving: Neuropsychological Assessment Battery®
Mazes (NAB-Mazes); (8) executive control: Trail Making
Test Part B (TMT-B). In all tests, higher scores reflected
better cognitive performance with the exceptions of TMT-
A and TMT-B, where the outcome measure is the number
of seconds needed to perform the task; thus, higher scores
reflected poorer cognitive performance.
SNP selection and genotyping
Blood samples were obtained close to the neu-
ropsychological assessment. The Tagger tool of Haplo-
view v.4.244 was used to select tagSNPs in linkage
disequilibrium (LD) (r2 > 0.7) with the remaining SNPs at
minor allele frequency (MAF) > 10% from the HapMap
phase III European samples. Functional SNP rs6265 and
SNPs most commonly associated with mental disorders or
cognitive dysfunction from the literature (rs2030324,
rs12273363, rs908867, and rs1491850) were prioritized as
tagSNPs45–48. In addition, rs11030094, rs11602246,
and rs4923463, which were absent from the HapMap
data, were included following Hennings, Honea, and
Neves49–51. In total, 11 SNPs were selected (Fig. S1).
Genotyping of the selected SNPs was performed using
the MassARRAYiPLEX platform (Agena Bioscience, for-
merly Sequenom, Inc.; San Diego, California). We used
mean methylation levels from the performed technical
replicas and discarded outlying values (standard deviation
>10%) as a quality control method. The genotyping assays
were performed at the genotyping facilities of CeGen in
the Santiago de Compostela Node (‘Centro Nacional de
Genotipado’).
Selection of genomic regions and quantitative DNA
methylation analysis
We selected promoters I and IV for our methylation
study analyses since these are promoters with more
consistent associations with psychiatric disorders27. We
used two assays to cover promoter I, with Assay 1 cov-
ering the region chr11: 27744025-27744278 and Assay 2
covering the region chr11: 27744414-27744653, and one
assay for promoter IV, covering chr11: 27722305-
27722675 (UCSC h19 assembly). The CpG sites ana-
lyzed in each region can be found in Table S1 of the
Supplementary Material.
DNA purification, bisulfite treatment, and quantitative
DNA methylation analysis using the MassArray platform
of SEQUENOM were performed as described52. Primers
were designed using MethPrimer (http://www.urogene.
org/ methprimer/). Primers were tagged to obtain an
appropriate product for in vitro transcription, prevent
abortive cycling and balance the PCR primer length
(forward primer tag: cagtaatacgactcactatagggagaaggct,
reverse primer tag: aggaagagag). The sequences of the
primers used for amplification are shown in Table S1 of
the Supplementary Material.
Statistical analyses
We processed data using SPSS 19.0 (SPSS, IBM, USA)
to perform descriptive and univariate analyses comparing
the MDD and HCs groups using the χ2 test for dichotomic
categorical variables and Student’s t-test for continuous
variables. We previously analyzed the distribution of
variables, and those following a skewed distribution were
log transformed (ln) to approximate normality, which was
the case for the HDRS and CTQ scores and two cognitive
tests (TMT-A and TMT-B).
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Association analysis at the individual SNP level was
performed as implemented in PLINK 1.953 to conduct
multivariate analysis based on linear regression. Statistical
significance was assessed by a permutation procedure to
estimate the significance of the best result (10,000 per-
mutations). Three different genetic models (dominant,
recessive, and additive) were considered. These analyses
represent an effective number of tests of 2.254; therefore,
the results were considered experiment-wise significant if
p value < 0.023 after the permutation procedure. The
analyses included sex, age, years of education, MDD
diagnosis, tobacco consumption, HDRS, STAI trait sub-
score and CTQ score as covariates.
An analysis of plausible mediation through methylation
variables in the relationship between SNPs and neurocog-
nitive variables was performed with the PROCESS macro of
SPSS version 21.0, developed by Hayes55. This method uses
bias-corrected bootstrap confidence intervals. The results
were considered significant when the bias-corrected 95%
confidence intervals did not contain zero.
Partial correlation analyses adjusted by age, gender, and
years of education were used to explore the relationship
between methylation measures and cognitive perfor-
mance. We conducted a stratified analysis by diagnosis
(HCs vs. MDD). In the MDD group, we also included
relevant clinical variables (HDRS, CTQ score, STAI trait
sub-score and antidepressant treatment).
Multiple linear regression analyses were carried out in
all participants to explore the association between
methylation variables and neuropsychological perfor-
mance, the latter being considered as dependent variables.
Separate multiple regression analyses were performed for
each methylation measure, each of which was considered
the main independent variable. We controlled for cov-
ariates and potential confounders including sex, age, years
of education, tobacco consumption, diagnostic group,
HDRS, STAI-trait sub-score and CTQ score. Anti-
depressant treatment was not included as a covariate
since this variable presents a high collinearity with MDD
diagnosis. Finally, we explored the association between
neuropsychological results and the interactions between
methylation status with sex, CTQ score and MDD diag-
nosis. Standardized beta coefficients will be reported.
Standardized beta coefficients are calculated by subtract-
ing the mean from the variable and dividing by its stan-
dard deviation. This results in standardized variables
having a mean of zero and a standard deviation of 1. The
standardization allows the comparison of all independent
variables in the equation. Standardized beta coefficients
reflect how many standard deviations a dependent vari-
able changes, per standard deviation increase in the pre-
dictor (independent) variable. As the standardized beta
coefficient reflects the strength of the association between
an independent variable (e.g. methylation of the promoter
IV of the BDNF gene) and the dependent variable (e.g.
visual memory task), a positive beta coefficient would
indicate a better cognitive performance in those indivi-
duals with a greater methylation whereas a negative beta
coefficient would indicate a poorer cognitive performance
in those individuals with a greater methylation.
The main analyses testing the hypotheses related to the
role of methylation of promoter I and IV of the BDNF
gene (mean methylation values) on each cognitive test (17
different cognitive measures) were adjusted for multiple
comparisons with the Benjamini-Hochberg procedure,
that allows controlling for the false discovery rate (FDR)56.
The results will be adjusted for different FDR (20%, 10%,
and 5%) taking into account 34 comparisons (17 cognitive
variables × 2 promoters). We further performed statistical
analyses under an exploratory approach when studying
association between specific BDNF methylation CpGs and
cognitive performance. For these analyses, the statistical
significance level was set at p < 0.05 (bilateral), without an
adjustment for multiple comparisons, as correction for
multiple testing is not strictly necessary in those analyses
that are exploratory in nature57.
Results
Univariate analysis
Demographic and clinical variables are shown in Table 1.
As expected, MDD patients showed higher HDRS scores
than HCs. MDD patients also showed significantly higher
scores in the CTQ and STAI trait subscore. In the cog-
nitive functioning analysis, MDD patients showed poorer
cognitive performance than HCs on all cognitive domains
(Table 2). Mean methylation values at each CpG site are
shown in Table S2 of the Supplementary Material.
Methylation levels were higher in HCs than in MDD with
significant differences in CpG 1 and 7.8.9 of promoter I
assay 1, CpG 14 of promoter I assay 2 and CpG 11, 13 and
15.16.17 of promoter IV.
Association analyses of individual SNPs
All genotyped polymorphisms were in Hardy-Weinberg
equilibrium and had call rates higher than 90%. After
correction for multiple testing using a 10,000 permuta-
tion procedure, two SNPs showed an association with
cognitive performance under a dominant model:
rs908867-T (standardized β: 0.228; P value: 0.013) was
associated with the BVMTR test outcome, and rs925946-
T (standardized β: 0.165; P value: 0.008) was associated
with the BACS-SC result. No other associations between
individual SNPs and cognitive performance were detec-
ted. We also tested for possible interactions between
significant SNPs with sex, CTQ and MDD diagnosis. One
significant result was found between the interaction of
rs925946-T and MDD diagnosis with the BACS-SC
result (MDD diagnosis [β: −0.25; p value: 0.005],
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rs925946 [β: 0.081; p value: 0.226], interaction MDD x
rs925946-T [β: 0.171; p value: 0.035]). We also performed
post hoc analyses of the association between individual
SNPs and treatment resistance in the MDD group but
found no significant association.
Mediation analysis
A significant mediation was found in the association
between rs908867 and the BVMTR test results through
differential methylation at the CpG 7.8.9 site of promoter
I. The bias-corrected bootstrap 95% CI indicated that the
indirect effect through methylation differences was sig-
nificant using a dominant model (Effect: 0.84 (SE 0.49),
95% CI, [0.15, 2.24]). No other significant mediations
were found.
Partial correlation analyses
We analyzed the correlation between methylation
variables and neuropsychological performance. The cor-
relation heat map of these partial correlation analyses
stratified by diagnosis is included in Figs. S2 and S3 of the
Supplementary Material. Antidepressant treatment was
not correlated with methylation measures.
Table 1 Demographic and clinical data of the
study sample
HCs (n= 70) MDD
(n= 64)
p value
Age (years) 54.5 (10.5) 57.1 (10.6) 0.171
Female gender, n (%) 44 (62.9%) 46 (71.9%) 0.267
Education (years) 11.6 (3.3) 9.7 (4.2) 0.004
Tobacco consumption
(cigarettes/day)
2 (5.3) 4.1 (8.6) 0.089
HDRS 0.7 (1.1) 12.3 (9.1) <0.001
Antidepressant treatment
(DDD)
0 (0) 2.3 (1.3) <0.001
Treatment resistance (Thase)a – – –
Stage 0 20 (31.3%)
Stage I 13 (20.3%)
Stage II 10 (15.6%)
Stage III 12 (18.8%)
Stage IV 9 (14.1%)
Stage V 0 (0%)
Childhood trauma
questionnaireb
34.3 (9.7) 38.5 (14.1) 0.043
STAI trait score 15.3 (8.6) 32.3 (13.7) <0.001
All variables presented in mean (SD), or n (%). Missing data: CTQ (1.5%), STAI
(1%)
HCs Healthy controls, MDD major depressive disorder, HDRS Hamilton
Depression Rating Scale, DDD Defined Daily Doses
aCriteria for treatment resistance stages were: non-resistant or any medication
trials, to date, judged to be adequate (Stage 0); failure of at least one adequate
trial of one major class of antidepressant (Stage I); failure of at least two
adequate trials of at least two distinctly different classes of antidepressants
(Stage II); Stage II resistance plus failure of an adequate trial of a tricyclic
antidepressant or a first augmentation strategy (lithium or thyroid hormone)
(Stage III); Stage III resistance plus failure of an adequate trial of an MAOI or a
second augmentation strategy (Stage IV); Stage IV resistance plus failure of an
adequate course of bilateral electroconvulsive therapy (Stage V)
Table 2 Neuropsychological performance in major
depressive disorder patients and healthy controls
HCs (n= 70) MDD (n= 64) p value
Cognitive domains
Verbal learning and memory
HVLT-R 23.86 (4.92) 20.37 (5.17) <0.001
Visual learning and memory
BVMT-R 22.66 (7.52) 14.72 (9.08) <0.001
RCFT – copy 30.84 (5.34) 27.70 (7.42) 0.006
RCFT – immediate recall 17.45 (6.36) 12.66 (6.57) <0.001
RCFT – delayed recall 17.76 (6.31) 12.13 (6.78) <0.001
Working memory
CBTT (non-verbal) 14.45 (3.74) 11.59 (3.76) <0.001
LNS (verbal) 13.72 (3.41) 10.58 (3.49) <0.001
Processing speed
TMT-Aa (seconds) 45.71 (24.00) 65.76 (38.41) <0.001
BACS-SC 47.73 (13.8) 33.11 (15.89) <0.001
Category fluency 23.74 (6.53) 20.05 (6.26) 0.001
Stroop Direct W 100.90 (15.81) 92.83 (22.67) 0.021
Stroop Direct C 70.93 (12.17) 61.17 (14.68) <0.001
Attention/vigilance
CPT-IP 2.52 (0.87) 1.99 (0.88) 0.002
Executive function
TMT-Ba (seconds) 82.24 (48.83) 149.19 (124.23) <0.001
NAB-Mazes 14.80 (6.86) 8.95 (7.19) <0.001
Stroop Direct WC 45.06 (12.76) 36.92 (11.04) <0.001
Stroop Direct Interference 3.62 (9.59) 0.38 (6.87) 0.026
All variables presented in mean (SD), or n (%). Missing data differed for cognitive
tests: HVLT-R (0.7%), BVMT-R (2.2%), LNS (4.4%), TMT A (1.5%), BACS-SC (1.5%),
Category fluency (0.7%), Stroop Direct W and C (0.7), CPT-IP (13.4%), TMT-B
(4.5%), NAB-Mazes (2.2%), Stroop Direct WC and Interference (1.5%)
HCs healthy controls, MDD major depressive disorder, HVLT-R Hopkins Verbal
Learning Test-Revised, BVMT-R Brief Visuospatial Memory Test-Revised, RCFT Rey
Complex Figure Test, CBTT Corsi Block-Tapping Test, LNS Letter Number Span,
TMT-A Trail Making Test part A, BACS-SC Brief Assessment of Cognition in
Schizophrenia-Symbol Coding, W words, C colors, CPT-IP Continuous Perfor-
mance Test-Identical Pairs, TMT-B Trail Making Test part B, NAB-Mazes
Neuropsychological Assessment Battery-Mazes, WC words-colors
aTMT-A and TMT-B raw scores are shown. P values calculated upon natural log-
transformed variables
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Multiple linear regression analyses
The results of multiple linear regression analyses of
mean methylation levels and neuropsychological perfor-
mance in all participants are shown in Table 3.
Promoter I
A higher promoter I mean methylation level was asso-
ciated with poorer performance in the LNS test, a result
which remained significant with a FDR of 20% but did not
reach significance at a FDR of 10%. This association was
also observed when analyzing methylation levels in the
region covered at Assay 2, while it did not appear in Assay
1. The results of the multiple linear regression analyses of
each CpG site in promoter I can be found in Tables S3
and S4 of the Supplementary Material. In Assay 1, CpG
site 7.8.9 was associated with poor results in most cog-
nitive domains (visual learning and memory, working
memory, processing speed, attention/vigilance, and
executive functioning). An inverse relationship was
observed in CpG site 10, where higher methylation pre-
dicted better results in visual learning and memory, pro-
cessing speed, attention/vigilance, and executive
functioning tests. In Assay 2, poorer cognitive functioning
in the LNS test was related to higher mean methylation
levels at CpG sites 3.4.5.6 and 9. Another significant
association was observed between higher methylation
values at the CpG 11 site and poor performance in the
BVMT-R test.
Promoter IV
Mean methylation levels at this promoter location were
significantly associated, at a FDR of 20%, to poorer per-
formance in BVMT-R, RCFT immediate and delayed
recall, LNS and fluency tests. However, at a 5% FDR only
RCFT immediate and delayed recall were significant.
Results of multiple linear regression analyses of each CpG
site in promoter IV can be found in Table S5 of the
Supplementary Material. CpG sites 5, 9, and 10 presented
an association with poorer cognition in several cognitive
domains (verbal and visual learning and memory, working
memory, processing speed and executive functioning).
Additionally, CpG site 13 showed an especially significant
association with worse performance in visual learning and
memory tasks (RCFT copy, immediate, and delayed recall).
Interaction analysis
The results of the analyses of significant interactions
between methylation variables and sex, CTQ score and
MDD diagnosis are shown in Table S6 of the Supple-
mentary Material. Regarding sex, the most consistent
interaction was found between CpG site 22.23 of pro-
moter IV, in which higher methylation values were asso-
ciated with better cognitive performance in women,
whereas an inverse association was observed in men.
Regarding interactions between methylation variables and
CTQ score, most significant interactions suggested that a
combination of higher methylation and a greater history
of childhood trauma were associated with poorer cogni-
tive functioning in attention, executive function and visual
Table 3 Results of multiple linear regression analyses of
mean methylation levels and neuropsychological
performance in all participants
Promoter I Promoter IV
Mean Assay 1 Assay 2 Mean
β β β β
Verbal learning and memory
HVLT-R 0.047 0.100 –0.030 –0.013
Visual learning and memory
BVMT-R 0.105 –0.042 –0.144 –0.152*
RCFT- copy 0.039 0.102 –0.047 –0.111
RCFT - immediate recall –0.060 <0.001 –0.108 –0.240**
RCFT - delayed recall –0.031 –0.009 –0.046 –0.261***
Working memory
CBTT (non-verbal) 0.089 0.083 0.065 –0.014
LNS (verbal) –0.193** –0.129 –0.207** –0.177*
Processing speed
TMT - A –0.011 –0.045 0.031 0.106
BACS SC 0.002 –0.022 0.029 –0.048
Fluency –0.014 –0.029 0.009 –0.175*
Stroop Direct W 0.049 0.080 –0.004 0.068
Stroop Direct C 0.054 0.059 0.029 –0.029
Attention/vigilance
CPT-IP 0.032 0.069 −0.019 −0.046
Executive function
TMT- B –0.069 –0.053 –0.066 0.061
NAB Mazes 0.006 0.026 –0.019 –0.124
Stroop Direct WC 0.105 0.087 0.091 <0.001
Stroop Direct
Interference
0.107 0.062 0.125 –0.010
Statistically significant results are highlighted as bold (*p < 0.05; **p < 0.01;
***p < 0.001).
Linear regressions were adjusted by sex, age, years of education, MDD diagnosis,
tobacco consumption, HDRS, STAI trait score and CTQ score.
β Standardized beta coefficient, HVLT-R Hopkins Verbal Learning Test-Revised,
BVMT-R Brief Visuospatial Memory Test-Revised, RCFT Rey Complex Figure Test,
CBTT Corsi Block-Tapping Test, LNS Letter Number Span, TMT-A Trail Making Test
part A, BACS-SC Brief Assessment of Cognition in Schizophrenia-Symbol Coding,
W words, C colors, CPT-IP Continuous Performance Test-Identical Pairs, TMT-B
Trail Making Test part B, NAB-Mazes Neuropsychological Assessment Battery-
Mazes, WC words-colors, MDD major depressive disorder, HDRS Hamilton
Depression Rating Scale, STAI State-Trait Anxiety Inventory, CTQ Childhood
Trauma Questionnaire
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and verbal memory. Finally, when exploring the interac-
tion with MDD diagnosis, we found that in both promoter
I and IV and in different cognitive domains, significant
associations between higher methylation and the presence
of MDD diagnosis could be found, where higher methy-
lation values were associated with poorer cognition in
MDD patients, while the inverse association was found
in HCs.
Discussion
We have studied the contribution of BDNF genetic and
epigenetic variations to cognitive functioning in MDD
patients and HCs. Our main findings include the asso-
ciation between two SNPs as well as promoter methyla-
tion levels with several cognitive tasks and statistically
significant interactions with sex, CTQ scores and MDD
diagnosis. In addition, differential methylation at the CpG
7.8.9 site of BDNF promoter I mediated the association
between the individual SNP rs908867 and visual memory.
In the present study exploring the relationship between
11 BDNF SNPs and cognitive functioning, two noncoding
SNPs (rs908867 and rs925946) were associated with
poorer performance on cognitive tasks dealing with visual
learning, memory and processing speed. Although most
research has focused on the role of the functional SNP
rs6265 in cognitive performance, there is evidence that
SNPs located in noncoding regions can also influence
gene regulation58. In this line, a well-characterized non-
coding SNP within BDNF is rs12273363, which has been
shown to regulate BDNF transcription by altering pro-
moter IV activity59. Although this particular SNP was not
associated in our sample, our findings related to associa-
tions with two noncoding SNPs (rs908867 and rs925946)
lend support to the hypothesis that noncoding SNPs may
also influence BNDF activity. Several associations have
been found relating BDNF SNP rs908867 with a variety of
clinical and neuroimaging phenotypes, including suicid-
ality60, treatment response in MDD48 and hippocampal
and cerebral atrophy49. Interestingly, in the study by
Januar and colleagues27, only major homozygous patients
showed an association between BDNF promoter methy-
lation and depression, and for CpG site 7.8.9, a trend
association was observed with depression, with
rs908867 significantly modifying this relationship. Our
results support the evidence of a relationship between
rs908867 and clinical phenotypes, including cognitive
dysfunction, an effect that seems to be mediated by
methylation at the CpG 7.8.9 site of BDNF promoter I.
One study including healthy individuals found an asso-
ciation between rs925946 and impairments in long-term
visual memory tasks61. Future studies focusing on the
influence of these SNPs on BDNF transcription regulation
are needed to describe the pathway through which they
could be involved in cognitive function.
Exploring the relationship between BDNF gene regula-
tion through methylation and neurocognitive perfor-
mance showed that, while higher methylation levels of
most regions were associated with poorer cognitive per-
formance in the whole sample and across all cognitive
domains, the effect of methylation in certain areas, such as
CpG site 10 in promoter I, was associated with better
cognitive function. These results suggest that hyper-
methylation at CpG site 10 could have a protective neu-
rocognitive effect. Another interesting association was
found in the promoter IV region, in which CpG site
13 showed a strong and specific association with impaired
visual learning and memory, while CpG sites 3, 9, and
10 seemed to be associated with deficits in multiple areas.
The mechanism through which differential methylation of
CpG site 13 can have a specific impact on visual learning
and memory, while other sites have a broader cognitive
effect, should be the focus of future studies. Taken as a
whole, our findings suggest an effect of BDNF gene pro-
moter methylation and neurocognitive performance. Our
results are in accordance with previous data from
epigenome-wide meta-analyses that reported an associa-
tion between DNA methylation in different genomic areas
and cognitive performance62.
To date, many studies have focused on the biological
mechanisms through which BDNF expression can influ-
ence cognitive performance. Previous studies based on
animal models examined the influence of BDNF variations
on different cognitive processes63–66. Some studies have
shown an association between BDNF gene methylation and
an increased risk of developing neurodegenerative dis-
orders67,68, but the results were not replicated in others69.
The cognitive tasks most frequently associated with
methylation variables in our results are related to memory
processes (visual, verbal, and working memory), which are
thought to be mediated by the hippocampus and pre-
frontal cortex. The mechanisms that regulate hippo-
campal function in memory have been widely studied.
Among other factors, BDNF is a key protein involved in
hippocampal neurogenesis70,71. BDNF function is subject
to epigenetic control, which is sensitive to external
modulating factors, including stress and childhood
trauma72. In this regard, animal studies have shown that
adolescent trauma is associated with elevated corticos-
terone levels and lower levels of BDNF in the dorsal
hippocampus73. DNA methylation represents an epige-
netic mechanism that contributes to the regulation of
BDNF transcription in the CNS and is therefore involved
in memory formation66. Research focusing on the influ-
ence of BDNF methylation and structural brain variations
in MDD patients has described associations with cortical
thickness, particularly in the prefrontal and occipital
areas74, hippocampal atrophy49 and white matter integrity
in the anterior corona radiata75.
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Our results also show that the association between
BDNF methylation and cognition can be moderated by
sex, childhood trauma or MDD diagnosis. In reference to
sex differences, previous human studies76 have reported
higher levels of DNA methylation of promoter IV of
BDNF in females. In line with these findings, animal
studies exploring whether maltreatment or nurturing care
is associated with differential methylation of BDNF within
the medial prefrontal cortex of adult rats have demon-
strated that methylation of DNA associated with exon IV
is increased in female maltreated rats31. Interestingly, in
our study, we found significant interactions between
methylation values and female sex with several cognitive
tasks dealing with executive function and processing
speed, which are known to involve the prefrontal cortex.
No previous studies have explored the moderation effect
of childhood trauma on the relationship between BDNF
methylation and cognitive functioning. In a recent twin
study, DNA methylation in several stress-related genes,
including BDNF, mediated the association between child-
hood trauma and depressive symptoms at adulthood77.
Animal studies have also demonstrated that early life
adversity produces persistent changes in DNA methylation
of BDNF that cause altered BDNF gene expression in the
adult prefrontal cortex30. Studies in humans have shown an
effect of childhood abuse on the epigenetic regulation of
hippocampal glucocorticoid receptor expression, which
could lead to cognitive dysfunction78.
Although the aim of our study was not to analyze dif-
ferences in BDNF methylation between diagnostic groups,
we observed significantly higher methylation levels at
specific promoter regions of the BDNF gene in HCs
compared to MDD patients, results which contrast with
previous findings showing greater methylation in
patients26,27. MDD diagnosis moderated the association
between methylation of BDNF and cognitive functioning
in memory and executive function, as MDD patients with
increased methylation showed a poorer cognitive profile.
As there are no previous studies exploring this issue in
relation to cognition, it is difficult to draw definitive
conclusions. Our findings suggest that methylation of
BDNF may contribute to the persistent cognitive deficits
observed in MDD patients.
To our knowledge, the present study is the first to
explore the effect of BDNF regulation through DNA
methylation on cognitive performance while adjusting for
modulating factors in MDD patients and HCs. Our results
suggest a relationship between methylation levels at spe-
cific promoter locations and cognitive function. There-
fore, this work suggests that future research on BDNF
regulation might help identify specific groups of MDD
patients who might benefit the most from intensive
antidepressant treatment targeting cognitive symptoms or
neurocognitive rehabilitation.
There are some limitations of our study that merit
discussion. First, we need to underscore that the asso-
ciation analysis between specific CpG sites and cognitive
performance was exploratory in nature. Thus, hypotheses
generated by these results need to be tested in further
confirmatory studies. Second, the small sample size of our
study might have reduced the statistical power to detect
small effect sizes. Third, clinical variables such as child-
hood trauma and anxiety questionnaires were retro-
spectively self-reported and could be influenced by recall
bias and depressive state. Fourth, patients were recruited
in a naturalistic setting, and therefore relevant differences
in clinical variables such as educational level existed
between groups. For this reason, we adjusted all analyses
by the factors that showed significant differences between
groups and that could influence gene methylation
according to previous literature. For example, a recent
meta-analysis reported an association between methyla-
tion at three specific genomic sites and depressive
symptomatology; therefore, all analyses were adjusted by
HDRS results79. Moreover, MDD patients were receiving
antidepressant treatment, which has been suggested to
influence DNA methylation at the BDNF gene35. How-
ever, no significant association between antidepressant
treatment dose (DDD) and DNA methylation at the
BDNF gene was identified in our sample. Fifth, patients
recruited from a tertiary source may differ from
community-based cases, which could limit the general-
ization of results. Finally, we assessed the levels of
methylation at the BDNF gene in peripheral blood cells.
Although it might be argued that methylation studied in
peripheral blood cells could be different than methylation
in the brain, recent studies suggest that peripheral BDNF
methylation closely reflects that of brain tissues80.
In summary, our study provides further insight into the
relationship between BDNF and cognitive performance,
suggesting that methylation of the BDNF gene influences
hippocampus- and prefrontal cortex-mediated cognitive
tasks and that female sex, childhood trauma and MDD are
moderators of these associations.
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